A. Sorete Arbore (Iasi, Romania), S. Niemann (Borstel, Germany), H. Stagg (London, United Kingdom)
Clinical experience of clofazimine in the treatment of MDR-TB
J. W. Yoo, J. Lyu, S. D. Lee, W. S. Kim, D. S. Kim, T. S. Shim (Seoul, Republic Of Korea)
|   |
Efficacy of treatment of MDR/XDR TB patients based on rapid diagnostics of M. tuberculosis drug resistance by GenoType MTBDRplus and GenoType MTBDRsl (Hain Lifescience GmbH, Germany)
I. Vasilyeva, A. Samoilova, E. Larionova, T. Smirnova, T. Bagdasaryan, L. Chernousouva (Moscow, Russian Federation)
| |
Risk factors for tuberculosis relapse in Polish patients
I. Siemion-Szczesniak, M. Korzeniewska-Kosela, J. Kus (Warsaw, Poland)
| |
Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine
N. Litvinenko, A. Barbova, A. Ghurilo (Kiev, Ukraine)
| |
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis
S. Cherenko, N. Lytvynenko (Kyiv, Ukraine)
| |
Pattern of drug resistance in TB patients treated at DR TB unit in tertiary care public sector hospital in Karachi Pakistan
S. Baig, S. Qayyum, N. Saifullal, N. Ahmed, I. Ahmed (Karachi, Pakistan)
| |
Immunotherapy using IL-2 potentially reverse disorders of Th1 /Th17 response in patients with MDR-TB
Q. Tan, R. Min, H. Wang, W. P. Xie, Z. H. Xu, M. Huang, W. G. Xu (Nanjing, China)
| |
A retrospective analysis of quinolone prescriptions for tuberculosis in two North Birmingham hospitals
G. Hagan, D. McLeod, N. Nathani (Birmingham, United Kingdom)
| |
Linezolid in the treatment of patients with MDR TB and XDR TB
S. Cherenko, N. Kibiziva, M. Pogrebnaya, J. Senko (Kiev, Ukraine)
| |
Prevalence of fluoroquinolon-resistance among different MDR tuberculosis cases in Ukraine
N. Litvinenko, S. Cherenko, A. Barbova, A. Ghurilo (Kiev, Ukraine)
| |
Adverse drug reactions to second line anti tuberculosis drugs: A prospective study in Mumbai, India
S. Natarajan, P. Subramanian (Mumbai, Thane, India)
| |
Characterization of extensively drug-resistant mycobacterium tuberculosis in Siberia
M. Dymova, O. Alkhovik, A. Cherednichenko, T. Petrenko, M. Filipenko (Novosibirsk, Russian Federation)
| |
Current status of fluoroquinolone use for treatment of tuberculosis in Korea
B. H. Kang, T. S. Shim, S. D. Lee, W. S. Kim, D. S. Kim (Seoul, Republic Of Korea)
| |
Spectrum of adverse drug reactions during MDR TB treatment
K. Mody, M. Kubal (Mumbai, India)
| |
High proportion of fluoroquinolone mono-resistant mycobacterium tuberculosis (MTB) strains in Pakistan (2010-2012)
K. Jabeen, F. Malik, R. Hasan (Karachi, Pakistan)
| |
Four cases, one family: A cluster of resistant tuberculosis
T. Sevim, O. Aktas, E. Aksoy, M. Agca, F. Tokgöz, T. Karagöz (Istanbul, Turkey)
| |
Impact of diabetes mellitus on drug-resistant tuberculosis treatment outcomes in Georgia – Cohort study
M. Kikvidze, L. Mikiashvili (Tbilisi, Georgia)
| |
Risk factors for acquired drug-resistant tuberculosis
E. Lesnic, V. Zlepca, V. Uzdris (Chisinau, Republic Of Moldova)
| |
A comparison of drug sensitivity pattern in category-I failure versus category-I relapse pulmonary TB patients attending a tertiary care hospital in South Punjab, Pakistan. Is WHO category-II ATT regimen appropriate?
M. I. Shahzad, M. A. Mushtaq, M. Z. Shaheen, H. Ghulam Murtaza (Multan, Pakistan)
| |